Latest Content

Dr. Joel Neal presents CHRYSALIS-2 data at ASCO 2026, highlighting a 3.5-year median survival and toxicity management for atypical EGFR-mutant NSCLC.

Dr. Sara Tolaney discusses the ASCENT-04 trial results for mTNBC and key strategies for oncology nurses to manage patient toxicities like diarrhea.

ASCO 2026 research highlights GLP-1 medications as a potential breast cancer prevention tool, showing a 30% risk reduction in retrospective analysis.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.

At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

Phase III ROSELLA data shows relacorilant plus nab-paclitaxel improves OS in platinum-resistant ovarian cancer with a manageable safety profile.

HR20013 plus dexamethasone improves delayed emesis control and daily functioning for patients on moderately emetogenic chemotherapy in the phase 3 PROTECT trial.

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

The FDA approved Cavhanza, a nilotinib ODT that allows co-administration with PPIs and H2RAs, easing dosing and administration for Ph+ CML patients.

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

ASCO 2026: The EMERALD-3 study shows adding STRIDE with or without lenvatinib to TACE significantly extends PFS for patients with unresectable HCC.